Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Amgen |
---|---|
Information provided by: | Amgen |
ClinicalTrials.gov Identifier: | NCT00872014 |
The purpose of this study is to determine whether AMG 386, in combination with Sorafenib, is effective in the treatment of advanced or inoperable Hepatocellular cancer in subjects who have not received any prior systemic therapy except surgery or locoregional therapy.
Disease status and disease progression will be assessed every 8 weeks. Subjects will remain on treatment until: progressive disease by RECIST criteria; death or loss to follow-up; or withdrawal of informed consent.
Condition | Intervention | Phase |
---|---|---|
Advanced or Inoperable Hepatocellular Carcinoma |
Drug: AMG 386 Drug: Sorafenib |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase 2, Open-Label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma |
Estimated Enrollment: | 30 |
Study Start Date: | June 2009 |
Estimated Study Completion Date: | March 2015 |
Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
AMG 386 10mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
|
Drug: AMG 386
AMG 386 will be administered 10mg/kg intravenously once weekly until disease progression, clinical progression, withdrawal of informed consent, unacceptable toxicity or death, whichever comes first.
Drug: Sorafenib
AMG 386 is the investigational product administered in this study. Sorafenib will be administered 400mg orally twice daily and indicated for the treatment of advanced or inoperable Hepatocellular Carcinoma. Sorafenib will be administered to all subjects until disease progression, clinical progression, withdrawal of informed consent, unacceptable toxicity or death, whichever comes first.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Amgen Inc. ( Global Development Leader ) |
Study ID Numbers: | 20080580 |
Study First Received: | March 12, 2009 |
Last Updated: | April 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00872014 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Liver Neoplasms Liver Diseases Digestive System Diseases Digestive System Neoplasms Carcinoma, Hepatocellular Gastrointestinal Neoplasms |
Hepatocellular Carcinoma Adenocarcinoma Protein Kinase Inhibitors Sorafenib Neoplasms, Glandular and Epithelial Carcinoma |
Liver Diseases Neoplasms by Histologic Type Digestive System Neoplasms Molecular Mechanisms of Pharmacological Action Carcinoma, Hepatocellular Antineoplastic Agents Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |
Carcinoma Liver Neoplasms Neoplasms Neoplasms by Site Digestive System Diseases Therapeutic Uses Adenocarcinoma Sorafenib Neoplasms, Glandular and Epithelial |